Cite
HARVARD Citation
Iwamoto, S. et al. (n.d.). A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial. Cancer medicine. pp. 4217-4227. [Online].